Abstract
Notes
Author Contributions
Monica Lucente (Conceptualization; Data curation; Writing – original draft)
Giulia Ragonesi (Data curation; Funding acquisition; Writing – original draft; Writing – review & editing)
Marco Sanguigni (Data curation; Software; Writing – original draft)
Fabio Sbaraglia (Conceptualization; Methodology; Supervision; Writing – review & editing)
Alessandro Vergari (Resources; Validation; Visualization; Writing – review & editing)
Rosa Lamacchia (Resources; Writing – review & editing)
Demetrio Del Prete (Data curation; Writing – review & editing)
Marco Rossi (Conceptualization; Writing – review & editing)
References
Table 1.
Case reports | Cases | Age | Indication | Timing | Intervention | Block-related adverse events |
---|---|---|---|---|---|---|
Muñoz et al. 2017 [2] | 1 | 7 years | Chest wall surgery | Postoperative | Single shot T8 | None reported |
14 ml bupivacaine 0.5% with epinephrine 5 μg/ml | ||||||
Adler et al. 2019 [4] | 1 | 3 weeks | Thoracic surgery | Preoperative catheter placement | Initial postoperative bolus through catheter 0.1% (0.25 mg/kg/h) ropivacaine in infusion for 48 h | None |
Catheter removed after 48 h | ||||||
Darling et al. 2018 [14] | 1 | 11 years | Iliac crest autograft | Preoperative | Single shot catheter tip at L2 | None reported |
Postoperative | 15 ml 0.5% ropivacaine intraoperative | |||||
11 ml 0.2% ropivacaine every 2 h on postoperative days 0-5 | ||||||
Balaban et al. 2019 [15] | 1 | 6 years | Femur fixation | Postoperative | Single shot T5 | None reported |
20 ml 0.25% bupivacaine | ||||||
Bosinci et al. 2021 [16] | 2 | 2 years | Hip surgery | Preoperative | Single shot T4 | None reported |
7 years | Lidocaine 2% 2 ml and levobupivacaine 0.25% 14 ml | |||||
Single shot lidocaine 2% 4 ml and levobupivacaine 0.25% 17 ml then continuous infusion levobupivacaine 0.125% 4–8 ml/h via infusion pump | ||||||
Catheter removed at 72 h | ||||||
Hernandez et al. 2018 [17] | 1 | 3 years | Thoracic surgery | Preoperative | Single shot T1 | None reported |
0.1 ml/kg bupivacaine 0.25% | ||||||
0.1 ml/kg lidocaine 1% | ||||||
Altıparmak et al. 2019 [20] | 1 | 2 days | Thoracic surgery | Preoperative | Single shot T4 T6 | None reported |
(32 weeks PCA) | 0.5 ml 0.25% bupivacaine (x2) | |||||
Gomez-Menendez et al. 2019 [21] | 1 | 13 months | Thoracic surgery | Preoperative | Single shot T4 | None reported |
5 ml bupivacaine 0.25% | ||||||
Hagen et al. 2019 [22] | 7 | 37 days– | Thoracic surgery | Preoperative | Single shot | None reported |
9 years | 0.5% bupivacaine + dexamethasone (1 bilateral) | |||||
Wyatt and Elattary 2019 [23] | 1 | 17 years | Thoracic surgery | Preoperative | Single shot T5 with catheter placement 25 ml 0.5% ropivacaine | None reported |
Continuous infusion through catheter 0.2% ropivacaine 8 ml/h during surgery 0.1% ropivacaine 10 ml/h postoperative | ||||||
Rescue bolus 4 ml bupivacaine 0.25% mixed + 1 ml lidocaine 2% upon arrival in ICU; Catheter removed at 96 h | ||||||
Aytuluk et al. 2020 [24] | 1 | 5 years | Chest tube insertion | Preoperative | Single shot T6-T7 | None reported |
7 ml 0.5% bupivacaine | ||||||
Çiftçi and Ekinci 2020 [25] | 1 | 12 years | Thoracic surgery | Preoperative | Single shot T5 | None reported |
15 ml 0.25% bupivacaine | ||||||
Gupta et al. 2020 [26] | 1 | 2 years | Thoracic surgery | Preoperative | Single shot T5 | None reported |
8 ml 0.375% ropivacaine + 10 μg clonidine | ||||||
Swenson Schalkwyk et al. 2020 [27] | 1 | 2 days | Thoracic surgery | Preoperative | Catheter T5-T6 with hydrodissection + 2 ml 3% chloroprocaine | None |
1 ml 0.1% at surgery | ||||||
Continuous infusion: 1.5% chloroprocaine at 0.25 ml/kg/h | ||||||
Catheter removed at 140 h | ||||||
Wong et al. 2018 [28] | 17 years | Cardiac surgery | Preoperative catheter placement and bolus; postoperative PIB | Bilateral catheters tip T7 | None reported | |
10 ml 0.5% ropivacaine (x2) preoperative, then postoperative alternating catheter boluses of 10 ml 0.1% ropivacaine every 60 min | ||||||
Catheter removal at 72 h | ||||||
Moore et al. 2018 [29] | 1 | 1 year | Abdominal surgery | Preoperative catheter placement and bolus; postoperative continuous infusion | Bilateral catheters T8-T10 | None reported |
1 ml 0.2% ropivacaine followed by 0.5 ml/h 0.2% ropivacaine intraoperative Postoperative 0.5 ml/h 0.1% ropivacaine until catheter removal 72 h postop | ||||||
Aksu and Gürkan 2018 [30] | 2 | 6 months | Nephrectomy | Preoperative | Single shot T12 | None |
7 years | 0.5 ml/kg 0.25% bupivacaine | |||||
Thomas and Tulgar 2018 [31] | 1 | 11 years | Abdominal surgery | Preoperative | Single shot bilateral T9 | None reported |
0.25% bupivacaine 0.5 ml/kg (x2) | ||||||
Munshey et al. 2018 [32] | 1 | 11 months | Open pyeloplasty | Preoperative | Catheter tip T8 | None reported |
Bolus 0.3 ml/kg ropivacaine 0.2% every hour during surgery, then 0.3 ml/kg ropivacaine 0.5% at end of surgery; Catheter removed at 48 h | ||||||
Aksu and Gürkan 2019 [33] | 3 | 8, 11, 13 years | Laparoscopy | Preoperative | Single shot bilateral T7 | None reported |
0.5 ml/kg 0.25% bupivacaine (max 20 ml) (x2) | ||||||
Ince et al. 2019 [34] | 1 | 13 years | Abdominal surgery | Preoperative | Single shot bilateral L2-3 | None reported |
LA not specified | ||||||
Karaca and Pınar 2019 [35] | 4 | 10–14 years | Abdominal surgery | Preoperative | Bilateral single-shot T7 | None |
Total 2.5 mg/kg bupivacaine | ||||||
Aydın et al. 2020 [36] | 1 | 9 months | Abdominal surgery | Postoperative | Single shot T10 + T11 | None |
Bupivacaine 0.25% (3 ml T10 + 3 ml T11) | ||||||
Ekinci et al. 2020 [37] | 1 | 2 years | Shock wave lithotripsy | Preoperative | Single shot T10 | None reported |
6 ml 0.25% bupivacaine | ||||||
Tsui et al. 2020 [38] | 1 | 16 years | Spinal surgery | Intraoperative surgical catheter placement | Bilateral catheter tips at T6 | None reported |
20 ml lidocaine 0.5% (x2) at end of surgery | ||||||
Postoperative boluses 20-22 ml 0.5% lidocaine alternating right and left side every 60 min; Catheter removed at 48 h | ||||||
Aksu and Gürkan 2020 [39] | 1 | 6 months | Genital surgery | Preoperative | Single-shot median sacral | None |
8 ml of 0.25% bupivacaine | ||||||
Ince et al. 2020 [40] | 1 | 4 years | Hip surgery | Preoperative | Single shot L4 | None |
ESPB in combination with pericapsular nerve block 0.25% bupivacaine (total 20 ml 0.25% bupivacaine) | ||||||
Baca et al. 2019 [41] | 1 | 15 years | Palliative pain | Catheters placed under general anesthesia in hospital before release to home care | Bilateral tunneled catheters T8 (advanced to T12) | None |
Single shot 11 ml 0.5% ropivacaine | ||||||
PIB 10 ml 0.2% ropivacaine every 2 h alternating sides | ||||||
Catheter removed after 7 days | ||||||
Kupeli et al. 2021 [42] | 9 | 2-10 years | Multiple surgery | Preoperative | Preoperative single shot upon catheter placement, 0.25% levobupivacaine 0.4 ml/kg | None reported |
Postoperative continuous infusion through perineurial catheter 1-5 ml/h 0.125% levobupivacaine | ||||||
Level T5 for thoracotomy; T8 for nephrectomy; T12-L2 for appendectomy and inguinal hernia; L1–2 for orchidopexy and ureterocele; and L4 for hip surgery Catheters removed within 24 h after surgery | ||||||
Le et al. 2020 [43] | 1 | 17 years | Ravitch procedure | Preoperative | Bilateral catheters T5 | None reported |
20 ml 0.2% ropivacaine preoperative | ||||||
Continuous infusion 6-8 ml/h ropivacaine 0.15% | ||||||
Rescue bolus 6 ml ropivacaine 0.15% on each side on postoperative day 1 Catheters removed at 72 h | ||||||
Bonfiglio et al. 2021 [44] | 1 | 19 years | Thoracoscopy | Preoperative catheter placement and bolus; postoperative continuous infusion + patient-controlled infusion | Single shot T4 | None reported |
18 ml of 0.25% levobupivacaine + 30 μg of dexmedetomidine | ||||||
Continous infusion 0.125% levobupivacaine 10 ml/h + PCI 5 ml with 60-min lockout | ||||||
Catheter removed on postoperative day 3 | ||||||
Bakshi et al. 2020 [45] | 2 | 3 years | Spine surgery | Preoperative catheter placement; catheter placement on postoperative day 4 | Intermittent bolus 6 ml 0.25% levobupivacaine every 8 h for 4 days | None |
4 years | Intermittent bolus of 5 ml 0.25% bupivacaine every 8 h for 4 days | |||||
Patel et al. 2019 [46] | 1 | 6 years | Thoracic surgery | Preoperative | Single shot T5 | None reported |
10 ml of 0.5% ropivacaine | ||||||
Continuous infusion through catheter 0.2 mg/kg/h ropivacaine | ||||||
Catheter removed at 96 h | ||||||
De la Cuadra-Fontaine et al. 2018 [47] | 1 | 3 years | Thoracic surgery | Preoperative catheter placement and bolus; postoperative continuous infusion + patient-controlled infusion | Single shot T9 8 ml of 0.25% levobupivacaine;Continuous infusion 0.1% levobupivacaine 3 ml/h + PCA 1.5 ml with 30-min lockout | None reported |
Catheter removed at 96 h | ||||||
Basaran and Akkoyun 2020 [48] | 1 | 1 days | Abdominal surgery | Preoperative | Single shot bilateral T7 | None reported |
(30 weeks PCA) | 0.5 ml 0.25% bupivacaine (x2) | |||||
Aksu and Gürkan 2019 [49] | 2 | 11 years | Abdominal surgery | Preoperative | Single shot T11 bilateral | None |
0.25% bupivacaine 0.5 ml/kg | ||||||
Aksu and Gürkan 2019 [50] | 2 | 2 years | Inguinal hernia repair | Preoperative | Single shot lumbar ESPB | None |
5 years | 0.25% bupivacaine 0.5 ml/kg (does not specify vertebral level) | |||||
Cesur et al. 2019 [51] | 5 | 3–12 years | Inguinal hernia repair | Preoperative | Single shot | None reported |
0.25% bupivacaine with a volume of 0.5 ml/kg (vertebral level not specified) | ||||||
Hernandez et al. 2018 [52] | 1 | 2 months | Inguinal hernia repair | Preoperative | Single-shot T6 | None |
0.2 ml/kg bupivacaine 0.25% | ||||||
0.2 ml/kg lidocaine 1% | ||||||
Elkoundi et al. 2019 [53] | 1 | 4 years | Hip surgery | Preoperative | Single shot L2 | None reported |
0.3 ml/kg 0.25% bupivacaine | ||||||
Uysal et al. 2020 [70] | 1 | 5 months | Diaphragmatic hernia | Postoperative | Single shot (twice) T6 T10 | None |
0.5 ml/kg 0.25% bupivacaine | ||||||
Paladini et al. 2019 [71] | 1 | 5 months | Thoracic surgery | Preoperative | Single shot T4 (twice) | None |
Postoperative | 4 ml 0.2% levobupivacaine after induction | |||||
4 ml 0.1% levobupivacaine before emergence | ||||||
Kaplan et al. 2018 [72] | 1 | 7 months | Thoracic surgery | Preoperative | Single shot T6 | None |
2 ml of 0.2% ropivacaine for hydrodissection and catheter placement, then continuous infusion through catheter 0.2% ropivacaine 1 ml/h | ||||||
Catheter removed at 72 h | ||||||
Gurbuz et al. 2021 [77] | 2 | 1 day | Thoraco-abdominal | Postoperative; preoperative | Single shot T4; T8 | Bradycardia 10 min after block (treated with atropine) in 1 case |
25 days | surgery | 0.75 ml 0.2% bupivacaine |
Table 2.
Case series | Cases | Age | Study design | Indication | Timing | Intervention | Block-related adverse events |
---|---|---|---|---|---|---|---|
Kaushal et al. 2020 [5] | 80 | Mean age 28.5 months | Prospective randomized single-blind comparative trial | Cardiac surgery | Preoperative | Single shot bilateral T3 | None |
1.5 mg/kg 0.2% ropivacaine (x2) vs. no block | |||||||
Macaire et al. 2020 [6] | 50 | Mean age 25 months | Prospective randomized double blind controlled trial | Cardiac surgery | Preoperative followed by postoperative programmed intermittent bolus regimen | Induction single shot in bilateral T3-T4 catheter | Accidental catheter removal or displacement |
0.1%-0.2% ropivacaine followed by postoperative PIB 0.1%-0.2% ropivacaine for 48 h vs. sham PIB with saline for 48 h | |||||||
Aksu et al. 2019 [7] | 57 | 1–7 years | Prospective double blind randomized trial | Pelvic small surgery | Preoperative | Single shot L1 | None |
ESPB vs. single shot quadratus lumborum block 0.5 ml/kg 0.25% bupivacaine | |||||||
Mostafa et al. 2019 [8] | 60 | 3–10 years | Prospective randomized control trial | Open splenectomy | Preoperative | Single shot bilateral T7 | None |
0.3 ml/kg 0.25% bupivacaine (x2) vs. bilateral sham ESPB 0.3 ml/kg normal saline (x2) | |||||||
Singh et al. 2020 [9] | 40 | 2–10 years | Prospective randomized control trial | Lower abdominal surgery | Preoperative | Single shot bilateral L1 | None |
0.5 ml/kg 0.25% bupivacaine (x2) vs. no block | |||||||
El-Emam et al. 2019 [10] | 60 | 6 months- | Prospective randomized control trial | Unilateral inguinal | Preoperative | Single shot L1 level ESPB vs. ilioinguinal/iliohypogastric nerve block, 0.5 ml/kg 0.125% bupivacaine + fentanyl 1 μg/ml injectate | None |
3 years | hernia repair | ||||||
Jambotkar and Malde, 2021 [19] | 30 | 1–12 years | Prospective observational study | Thoracotomy | Preoperative | Single shot T4 | None |
0.25% bupivacaine 0.3 ml/kg | |||||||
Aksu and Gurkan, 2019 [69] | 141 | 0.25–17 years | Retrospective cohort study | Thoracic, abdominal and pelvic surgery | Preoperative | Unilateral (112) or bilateral (29) single shot T4 to S4 | None |
0.25% bupivacaine 0.5 ml/kg (max 20 ml) | |||||||
Munshey et al. 2020 [73] | 22 | 11 months–17 years | Retrospective cohort study | Thoracic, abdominal, hip surgery | Preoperative (postoperative for one patient) followed by intraoperative and postoperative programmed intermittent bolus regimen | Catheter ESPB (17 unilateral, 5 bilateral; 22 thoracic, 5 lumbar) with median loading dose 0.4 ml/kg ropivacaine 0.5%, intraoperative bolus of 0.3 ml/kg/h ropivacaine 0.2%, postoperative programmed intermittent bolus maximum 0.5 mg/kg/h | Local edema and tenderness |